Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma

Precision oncology requires sensitive and specific clinical biomarkers. Carbohydrate Antigen 19-9 (CA19-9) is widely used in pancreatic ductal adenocarcinoma (PDA) but lacks sensitivity and specificity. Nearly all PDAs harbor somatic KRAS mutations, nominating circulating tumor DNA (ctDNA) KRAS as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Inna, Raymond, Victoria M., Geis, Jennifer A., Collisson, Eric A., Jensen, Benny V., Hermann, Kirstine L., Erlander, Mark G., Tempero, Margaret, Johansen, Julia S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716690/
https://www.ncbi.nlm.nih.gov/pubmed/29228650
http://dx.doi.org/10.18632/oncotarget.22080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716690/
https://www.ncbi.nlm.nih.gov/pubmed/29228650
http://dx.doi.org/10.18632/oncotarget.22080

Ejemplares similares